(Q46653990)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

invasive fungal infections

5 January 2020

main subject

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Daniela Damiani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

8

Pierluigi Viale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

Anna Candoni

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Rosalba Mestroni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Angela Michelutti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Federico Silvestri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Maurizio Castelli

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Renato Fanin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

227-233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16104879%20AND%20SRC:MED&resulttype=core&format=json

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Aspergillosis case-fatality rate: systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogeneic bone marrow transplant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Malignancy: Granulocyte Colony Stimulating Factor Increases the Efficacy of Conventional Amphotericin in the Treatment of Presumed Deep-Seated Fungal Infection in Neutropenic Patients following Intensive Chemotherapy or Bone Marrow Transplantation f

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X

Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2005.00500.X